The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Recurrence outcomes from the ESOPEC Trial in esophageal cancer
Jens Hoeppner, MD, University of Bielefeld, Bielefeld, Germany, discusses recurrence patterns from the Phase III ESOPEC trial (NCT02509286) of perioperative FLOT-based chemotherapy or preoperative chemoradiotherapy with CROSS in patients with esophageal adenocarcinoma. Findings indicate improved recurrence-free and distant metastasis-free survival with FLOT. Distant recurrence was the predominant driver of poor outcomes and occurred less frequently in patients receiving FLOT. These results highlight the potential of perioperative chemotherapy to reduce systemic relapse and improve long-term disease control in this population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
